Erschienen in:
Open Access
01.09.2012 | Meeting abstract
Lymphoma risk in systemic lupus: effects of treatment versus disease activity
verfasst von:
AE Clarke, S Bernatsky, KH Costenbader, MB Urowitz, DD Gladman, PR Fortin, M Petri, S Manzi, DA Isenberg, A Rahman, D Wallace, C Gordon, C Peschken, MA Dooley, EM Ginzler, C Aranow, SM Edworthy, O Nived, S Jacobsen, G Ruiz-Irastorza, E Yelin, SG Barr, L Criswell, G Sturfelt, L Dreyer, I Blanco, L Gottesman, CH Feldman, R Ramsey-Goldman
Erschienen in:
Arthritis Research & Therapy
|
Sonderheft 3/2012
Einloggen, um Zugang zu erhalten
Excerpt
We recently evaluated the risk of malignancy in SLE by linking a multi-site international SLE cohort with regional tumor registries. Across 28 centers, 15,980 patients were observed for 119,846 (average 7.5) person-years. In total, 641 cancers occurred, for an overall standardized incidence ratio (SIR) of 1.14 (95% CI = 1.06 to 1.24). Hematologic malignancies were substantially increased (SIR = 3.01, 95% CI = 2.47 to 3.62), particularly non-Hodgkin's lymphoma (NHL; SIR = 4.36, 95% CI = 3.43 to 5.47) and leukemia (SIR = 1.76, 95% CI = 1.04 to 2.78) [
1]. Yet the relative influence of treatment versus disease activity is unknown. Our objective was to determine the relative importance of drugs versus disease activity in mediating the increased risk of lymphoma. …
